We recently published our article 5 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market. To read the full article, head on to 10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market. In this piece, we take a closer look at Scholar Rock Holding Corporation (NASDAQ:SRRK) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.

Novo Nordisk A/S (NYSE: NVO) helped transform obesity treatment from a relatively overlooked pharmaceutical category into one of Wall Street’s biggest healthcare stories. The success of GLP-1 weight-loss drugs proved that effective obesity medicines could generate blockbuster sales, attract millions of patients and reshape how doctors treat metabolic disease.

The opportunity is enormous. Obesity affects hundreds of millions of people worldwide and is associated with type 2 diabetes, cardiovascular disease, fatty-liver disease, sleep apnea and other serious health conditions. Yet only a small percentage of eligible patients currently receives modern prescription weight-loss treatments. That gap explains why analysts believe the global weight-loss drug market could eventually exceed $100 billion in annual sales.

The Next Winners May Offer More Than Weight Loss

The next phase of the obesity drug boom will not be based solely on which treatment produces the highest percentage of weight loss. Drugmakers are now developing oral GLP-1 pills, monthly injections, dual- and triple-hormone therapies, amylin-based medicines and treatments designed to preserve muscle while patients lose fat.

Here is an important piece of trivia: weight loss does not come entirely from body fat. Patients may also lose lean tissue, including muscle, which has pushed biotechnology companies to develop complementary treatments that improve the quality of weight loss. Others are working on easier dosing, fewer gastrointestinal side effects and medicines that may also improve liver, heart and metabolic health.

Oral obesity treatments could become especially disruptive. Many patients dislike needles, while pills may be easier to manufacture, distribute and use. A successful weight-loss pill would not necessarily need to outperform every injectable treatment. Convenience alone could allow it to capture a meaningful portion of the growing obesity treatment market.

Why Biotech Stocks Are Entering the Spotlight

Novo Nordisk A/S (NYSE: NVO) remains the company framing this story, but it is not included in the top 10 ranking. Instead, the countdown focuses on biotechnology stocks attempting to benefit from the market Novo Nordisk helped create.

Some of these companies are developing direct competitors to existing GLP-1 drugs. Others are pursuing different mechanisms, longer-lasting treatments or therapies that could eventually be prescribed alongside popular weight-loss medicines. Their success could lead to major commercial partnerships, acquisition interest or sharp valuation increases.

The risks are equally significant. Obesity drug trials are expensive, clinical results can disappoint and smaller biotechnology companies may need additional financing before reaching commercialization. Investors searching for the best biotech stocks to buy now should therefore examine clinical progress, cash reserves, safety data, competitive advantages and upcoming catalysts—not just ambitious weight-loss claims.

The following countdown identifies 10 biotechnology stocks positioned to participate in the next stage of the $100 billion weight-loss drug market, beginning with number 10 and moving toward the company offering the strongest combination of scientific promise, market opportunity and investment potential.

CHECK THIS OUT: Top 10 AI-Powered Healthcare Stocks That Can Make You Rich and Top 10 Healthcare Stocks That Could Turn a $1000 Investment Into Something Bigger.

Our Methodology

In order to arrive to our list of the 10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market, we examined the trending biotech stocks and based our ranking on each company’s clinical progress, treatment differentiation, market opportunity, financial position, upcoming catalysts, partnership potential and overall risk-reward profile within the rapidly growing obesity and metabolic-disease market.

5 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market

3. Scholar Rock Holding Corporation (NASDAQ:SRRK)

Rather than developing another conventional GLP-1 medicine, Scholar Rock Holding Corporation (NASDAQ: SRRK) specializes in myostatin biology. Myostatin is a naturally occurring protein that limits skeletal-muscle growth, and the company is developing selective antibodies intended to preserve or increase muscle mass. This approach could become increasingly valuable as millions of patients begin using powerful obesity drugs and physicians pay greater attention not only to how much weight patients lose, but also to whether that lost weight comes from fat or metabolically important lean tissue.

The company produced encouraging proof-of-concept results from the Phase 2 EMBRAZE trial, which evaluated apitegromab alongside tirzepatide in adults with obesity or overweight. After 24 weeks, patients receiving the combination preserved an additional 4.2 pounds of lean mass compared with those receiving tirzepatide alone, representing 54.9% greater lean-mass preservation. Approximately 85% of the weight lost in the combination group came from fat, compared with about 70% among patients receiving tirzepatide alone. Participants taking apitegromab with tirzepatide lost 12.3% of their body weight, while those taking tirzepatide alone lost 13.4%, indicating that the antibody improved the composition of the weight loss while preserving most of tirzepatide’s overall effect. Apitegromab was also generally well tolerated, with no serious adverse events or treatment discontinuations considered related to the antibody.

Akshay Vaishnaw, M.D., Ph.D., President of Research and Development at Scholar Rock Holding Corporation (NASDAQ: SRRK), said the results validated the company’s belief that selective myostatin inhibition could support “healthier weight loss” for patients using GLP-1 therapies by preserving lean mass. That positioning gives Scholar Rock Holding Corporation (NASDAQ: SRRK) a potentially complementary role in the obesity market. The company would not necessarily need to compete directly with blockbuster drugs from Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), or other incretin developers. Instead, its muscle-preservation treatments could potentially be added to successful obesity medicines, turning major GLP-1 manufacturers into possible partners rather than only competitors.

The next important obesity-related asset is SRK-439, a subcutaneously administered myostatin inhibitor designed to bind selectively to the pro- and latent forms of myostatin without binding related proteins such as GDF11 or Activin A. Scholar Rock Holding Corporation (NASDAQ: SRRK) has already started a Phase 1 study of SRK-439 in healthy volunteers and expects topline results during the second half of 2026. Management believes the candidate could potently inhibit myostatin and increase muscle mass, potentially giving the company a more purpose-built treatment for obesity and other muscle-related conditions than apitegromab.

Scholar Rock Holding Corporation (NASDAQ: SRRK) also has a major near-term opportunity outside obesity. Apitegromab is under FDA review for spinal muscular atrophy, with a Prescription Drug User Fee Act action date of September 30, 2026. The company said it was preparing to launch the medicine immediately following a potential approval. As of March 31, 2026, Scholar Rock Holding Corporation (NASDAQ: SRRK) held approximately $479.9 million in cash, cash equivalents, and marketable securities, although it reported a quarterly net loss of $105.5 million and had not yet generated product revenue. This means the company has meaningful financial resources, but it is also spending heavily as it prepares for commercialization and advances several clinical programs.

YOU MUST READ THIS: 10 Biotech Stocks That Could Turn Medicine Into Wall Street’s Next Gold Rush

Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.